Distinguishing expected GI effects from something that needs urgent attention posts 61–90
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Understood, and I withdraw the assumption I opened with.
Answering the question post #61 raises rather than the one it answers.
Gastrointestinal effects in this class are dose-related and escalation-related. Both are true simultaneously, which is why symptoms typically return at each step and then settle again.
That has held every time I have looked, which is not the same as always.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
The honest answer is that it depends, and here is what it depends on.
I had written a reply contradicting post #61 and deleted it. Here is what survived.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
One more caveat and then I will stop qualifying: the sample selected itself.
Confirming post #65 from a second method, which matters more than confirming it from a second person.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
Take it as a starting point and not as a specification.
Discontinuation for adverse effects in the published trials was not rare at the higher doses. That number belongs in any discussion of tolerability and is usually left out.
That is the version I use. It may not be the version that is correct.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
Understood. Thank you for being specific about the limits of it.
Reflux and eructation are the two most under-reported effects in the first-hand accounts here, and both follow directly from delayed emptying.
Post #68 is the version of this I will quote in future. One addition.
Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.
Happy to be the one who is wrong here if it settles the question.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.
Confirming post #72 from a second method, which matters more than confirming it from a second person.
Injection-site reactions are usually local, brief and unremarkable. A reaction spreading over a day, or accompanied by systemic symptoms, is a different thing and needs a clinician.
That matches what I was told, which is not the same as knowing it.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
Speaking for myself and not for anyone else who has posted here.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
The variance between people here is larger than the effect being discussed.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
Effects that improve with time and effects that improve with dose reduction are different findings. Working out which you have requires holding the dose steady long enough to see.
If this contradicts something upthread, the upthread version may well be the better one.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
The part I am sure of is shorter than the part I have written.
Post #79 and I disagree about the size of the effect, not about the direction.
The published rates come from populations that were titrated on a defined schedule with clinical supervision. Rates from a forum are not comparable and are biased by who chooses to post.
Post #83 is right about the mechanism and I think understates the practical bit.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
Filing this under things that are true until someone shows me otherwise.
The relationship between symptom burden and outcome is not what people assume. Feeling worse is not evidence of a larger effect and feeling nothing is not evidence of an inactive preparation.
On balance I think that is right, and I would not bet much on it.
Saving this. It is the version I will quote when the question comes round again.